like all other appointments I only can see higher costs and higher cash burn. Cant follow for what all this appointments are for if we have not a single product not even a phase 3 trial as far as I know. Let apart not even a well known Private Equity company on board. We are down 90% btw. Market already priced in the value of all other appointments I guess. IMO and perception
Ann: Imugene Appoints Kim Drapkin as Non-Executive Director, page-80
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
0.003(6.82%) |
Mkt cap ! $349.6M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.9¢ | 4.5¢ | $963.9K | 20.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 1558493 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 1495843 | 7 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |